-
公开(公告)号：US20150284466A1
公开(公告)日：2015-10-08
申请号：US14747226
申请日：2015-06-23
CPC分类号： C07K16/2866 , A61K9/0019 , A61K9/19 , A61K39/39591 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , C07K2317/24 , C07K2317/94
摘要： The present invention relates to antibody-containing lyophilized formulations free from reducing sugars, non-reducing sugars, sugar alcohols or polysaccharides as excipients and including one or more amino acid selected from the group consisting of arginine, histidine, lysine, serine, proline, glycine, alanine and threonine or a salt thereof.
-
公开(公告)号：US20220281988A1
公开(公告)日：2022-09-08
申请号：US17752978
申请日：2022-05-25
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
公开(公告)号：US20210246216A1
公开(公告)日：2021-08-12
申请号：US17242199
申请日：2021-04-27
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
公开(公告)号：US20240317869A1
公开(公告)日：2024-09-26
申请号：US18656957
申请日：2024-05-07
IPC分类号： C07K16/28 , A61K9/00 , A61K39/00 , A61K39/395 , A61K47/18 , A61K47/20 , A61K47/26 , C07K1/14
CPC分类号： C07K16/2866 , A61K39/3955 , A61K39/39591 , A61K47/183 , A61K47/20 , A61K47/26 , C07K1/14 , A61K9/0019 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
公开(公告)号：US20200079857A1
公开(公告)日：2020-03-12
申请号：US16390197
申请日：2019-04-22
摘要： The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.
-
公开(公告)号：US20230340134A1
公开(公告)日：2023-10-26
申请号：US18335789
申请日：2023-06-15
CPC分类号： C07K16/2866 , A61K39/39591 , A61K47/183 , A61K47/26 , C07K1/14 , A61K39/3955 , A61K47/20 , A61K9/0019
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
公开(公告)号：US20230167183A1
公开(公告)日：2023-06-01
申请号：US18162368
申请日：2023-01-31
CPC分类号： C07K16/2866 , A61K39/3955 , A61K39/39591 , A61K47/20 , A61K47/26 , A61K47/183 , C07K1/14 , A61K9/0019
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
8.发明申请公开(公告)号：US20170112930A1
公开(公告)日：2017-04-27
申请号：US15400355
申请日：2017-01-06
发明人： Daisuke KAMEOKA , Masaya Yasutake
IPC分类号： A61K39/395 , A61K47/18
CPC分类号： A61K39/39591 , A61K9/0019 , A61K9/08 , A61K47/18 , A61K47/183 , C07K16/2866 , C07K2317/94
摘要： Addition of argininamide or valinamide to a highly concentrated antibody solution was found to lead to remarkable stabilization, in particular, stabilization against photostress.
-
公开(公告)号：US20160090419A1
公开(公告)日：2016-03-31
申请号：US14963414
申请日：2015-12-09
IPC分类号： C07K16/28 , A61K47/26 , A61K47/20 , A61K39/395 , A61K47/18
CPC分类号： C07K16/2866 , A61K9/0019 , A61K39/3955 , A61K39/39591 , A61K47/183 , A61K47/20 , A61K47/26 , A61K2039/505 , C07K1/14 , C07K2317/24 , C07K2317/76
摘要： The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.
摘要翻译： 要解决的问题是提供稳定且适合于皮下给药的抗体制剂，其中在长期储存期间可防止二聚化和脱酰胺化。 本申请涉及一种稳定的含抗体的液体制剂，其特征在于含有精氨酸和甲硫氨酸。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.018 秒)
